Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share compared to net loss of $2.4 million or $0.19 per share for the third quarter of 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MNPR:
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
- MNPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Monopar presents data showing tumor reduction benefit of camsirubicin
- Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
- Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference